Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) has provided an update.
Immunovia AB has launched the PancreaSure test, a blood test designed for the early detection of pancreatic cancer in high-risk individuals. The test is now available at several leading U.S. pancreatic cancer surveillance programs, with initial orders already placed. The PancreaSure test, which has demonstrated a sensitivity of 78% and specificity of 94%, is expected to significantly improve early detection and treatment outcomes. The launch has been welcomed by patient advocacy organizations, and the company plans to begin insurance billing in 2026.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company specializes in developing and commercializing blood-based tests to detect proteins and antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and patient advocacy groups to make these tests available to high-risk individuals.
Average Trading Volume: 9,228,670
Technical Sentiment Signal: Hold
Current Market Cap: SEK182.4M
See more data about IMMNOV stock on TipRanks’ Stock Analysis page.